MedTrace Logo

Cerebrolysin REGistry Study in Stroke

NCT02541227 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 1823

Last updated 2022-04-06

No results posted yet for this study

Summary

Investigation of clinical practices, safety and effectiveness of Cerebrolysin in routine treatment of patients with acute ischemic stroke.

Conditions

Interventions

DRUG

Cerebrolysin

Cerebrolysin dosage, frequency and duration follows local clinical practice in accordance with the terms of the local marketing authorization

Sponsors & Collaborators

  • SITS International

    collaborator NETWORK

  • Ever Neuro Pharma GmbH

    lead INDUSTRY

Principal Investigators

  • Kennedy Lees, MD · University of Glasgow

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-05-31
Primary Completion
2017-12-31
Completion
2021-12-31

Countries

  • Austria

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02541227 on ClinicalTrials.gov